Dieta e dispersão de sementes por Cerdocyon thous (Linnaeus) (Carnívora, Canidae), em um fragmento florestal no Paraná, Brasil Diet and seed dispersal by Cerdocyon thous (Linnaeus) in a forest fragment in Paraná (Carnivora, Canidae)

Embora o cachorro-do-mato, Cerdocyon thous (Linnaeus, 1706), seja um Canidae relativamente comum, não há muita informação sobre sua dieta e seu papel como dispersor de sementes nos diferentes habitats onde ocorre. O objetivo deste trabalho foi o de reportar a dieta de C. thous e sua importância como dispersor e/ou predador de sementes, e ainda testar a taxa de germinação de sementes após passar pelo trato digestório do animal. O estudo foi realizado em um fragmento (680 ha) de Floresta Estacional Semidecidual, o Parque Estadual Mata dos Godoy, localizado na cidade de Londrina, Paraná, sul do Brasil. A metodologia consistiu de coletas de fezes de C. thous, as quais foram analisadas em laboratório para identificar os itens consumidos. Nos testes de germinação, as sementes foram dispostas para germinar em placas de Petri com algodão umedecido em água. Noventa e três amostras fecais com 219 itens de origem vegetal e animal foram registradas, sendo 36,52% contendo restos de pequenos roedores, 24,19% de gramíneas, 13,24% de aves, 10,47% de insetos, 6,39% de Syagrus romanzoffiana (Cham.) Glassm., 4,6% de outros itens de origem animal e 4,54% de outros itens de origem vegetal. Ainda, C. thous dispersou nove espécies de plantas, com relevante importância para a germinação de algumas sementes que passaram pelo trato digestório do animal, exceto para S. romanzoffiana, cujas sementes não germinaram nas condições de laboratório. Conclui-se que, C. thous apresentou uma dieta generalista e oportunista, sobrevivendo em áreas degradadas e antrópicas, e agindo como dispersor de sementes nestes locais.<br>Although the crab eating fox, Cerdocyon thous (Linnaeus, 1706), is a relatively common Canidae, there isn't much information about its diet and its role as a seed disperser in the different habitats where it occurs. The aim of this work was to report the diet of the C. thous and its importance as a seed disperser and / or a seed predator and to test the rate of germination of the seeds after passing through the digestive tract of the animal. The work was carried out in a 680 ha fragment of the Semidecidual Seasonal Forest in the Parque Estadual Mata dos Godoy, located in the city of Londrina-Paraná, south of Brazil. The methodology consisted of the collection of excrement of C. thous which were analyzed in laboratory for identification of consumed items and seeds. In germination tests, the seeds were placed to germinate in Petri dishes with wet cotton. Ninety-three animal feces samples, with 219 animal and vegetable items were registered, being 36.52% remaining portions of small rodents, 24.19% of grasses, 13.24% of birds, 10.47% of insects, 6.39% of Syagrus romanzoffiana (Cham.) Glassm., 4.6% of other items of animal origin and 4.54% of items vegetable origin. In addition, C. thous dispersed nine species of plants, with relevant importance to the germination of some seeds, which passed through the digestive tract, except for the most consumed of fruit, S. romanzoffiana, whith no seed germination at all in lab conditions. In conclusion, C. thous has a generalistc and opportunistc diet, surviving in degraded and anthropic areas and being able to act as a seed disperser

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice : A multicentre cohort study

Background: The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS). Methods: Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014-2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL) < 50 copies/ml and < 200 copies/ml at 24 and 48 weeks after starting this regimen, stratified by baseline VL (< 50 or ≥ 50 copies/ml at the start of the regimen). Results: We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL < 50 copies/ml and 29 (74.4%) had ≥ 50 copies/ml. Among patients with baseline VL < 50 copies/ml, 85.7% and 80.0% had VL < 50 copies/ml at 24 and 48 weeks, respectively, and 100% had VL < 200 copies/ml at 24 and 48 weeks. Among patients with baseline VL ≥ 50 copies/ml, 42.3% and 40.9% had VL < 50 copies/ml and 69.2% and 68.2% had VL < 200 copies/ml at 24 and 48 weeks. During the first 48 weeks, no patients changed their treatment due to toxicity, and 4 patients (all with baseline VL ≥ 50 copies/ml) changed due to virological failure. Conclusions: EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads

Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

Outcomes of people living with HIV (PLWH) developing non-AIDS events (NAEs) remain poorly defined. We aimed to classify NAEs according to severity, and to describe clinical outcomes and prognostic factors after NAE occurrence using data from CoRIS, a large Spanish HIV cohort from 2004 to 2013. Prospective multicenter cohort study. Using a multistate approach we estimated 3 transition probabilities: from alive and NAE-free to alive and NAE-experienced ("NAE development"); from alive and NAE-experienced to death ("Death after NAE"); and from alive and NAE-free to death ("Death without NAE"). We analyzed the effect of different covariates, including demographic, immunologic and virologic data, on death or NAE development, based on estimates of hazard ratios (HR). We focused on the transition "Death after NAE". 8,789 PLWH were followed-up until death, cohort censoring or loss to follow-up. 792 first incident NAEs occurred in 9.01% PLWH (incidence rate 28.76; 95% confidence interval [CI], 26.80-30.84, per 1000 patient-years). 112 (14.14%) NAE-experienced PLWH and 240 (2.73%) NAE-free PLWH died. Adjusted HR for the transition "Death after NAE" was 12.1 (95%CI, 4.90-29.89). There was a graded increase in the adjusted HRs for mortality according to NAE severity category: HR (95%CI), 4.02 (2.45-6.57) for intermediate-severity; and 9.85 (5.45-17.81) for serious NAEs compared to low-severity NAEs. Male sex (HR 2.04; 95% CI, 1.11-3.84), ag

Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

The aim of this transversal study was to describe the virological and immunological features of HIV-infected youths transferred from pediatric to adult care units since 1997 vs. the non-transferred patients from the Madrid Cohort of HIV-infected children and adolescents in Spain. We included 106 non-transferred and 184 transferred patients under clinical follow-up in 17 public hospitals in Madrid by the end of December 2017. Virological and immunological outcomes were compared in transferred vs. non-transferred patients. ART drug resistance mutations and HIV-variants were analyzed in all subjects with available resistance pol genotypes and/or genotypic resistance profiles. Among the study cohort, 133 (72.3%) of 184 transferred and 75 (70.7%) of 106 non-transferred patients had available resistance genotypes. Most (88.9%) of transferred had ART experience at sampling. A third (33.3%) had had a triple-class experience. Acquired drug resistance (ADR) prevalence was significantly higher in pretreated transferred than non-transferred patients (71.8% vs. 44%; p = 0.0009), mainly to NRTI (72.8% vs. 31.1%; p < 0.0001) and PI (29.1% vs. 12%; p = 0.0262). HIV-1 non-B variants were less frequent in transferred vs. non-transferred (6.9% vs. 32%; p < 0.0001). In conclusion, the frequent resistant genotypes found in transferred youths justifies the reinforcement of HIV resistance monitoring after the transition to avoid future therapeutic failures

Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress?

Background. High uptake of antiretroviral treatment (ART) is essential to reduce human immunodeficiency virus (HIV) transmission and related mortality; however, gaps in care exist. We aimed to construct the continuum of HIV care (CoC) in 2016 in 11 European Union (EU) countries, overall and by key population and sex. To estimate progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, we compared 2016 to 2013 estimates for the same countries, representing 73% of the population in the region. Methods. A CoC with the following 4 stages was constructed: number of people living with HIV (PLHIV); proportion of PLHIV diagnosed; proportion of those diagnosed who ever initiated ART; and proportion of those ever treated who achieved viral suppression at their last visit. Results. We estimated that 87% of PLHIV were diagnosed; 92% of those diagnosed had ever initiated ART; and 91% of those ever on ART, or 73% of all PLHIV, were virally suppressed. Corresponding figures for men having sex with men were: 86%, 93%, 93%, 74%; for people who inject drugs: 94%, 88%, 85%, 70%; and for heterosexuals: 86%, 92%, 91%, 72%. The proportion suppressed of all PLHIV ranged from 59% to 86% across countries. Conclusions. The EU is close to the 90-90-90 target and achieved the UNAIDS target of 73% of all PLHIV virally suppressed, significant progress since 2013 when 60% of all PLHIV were virally suppressed. Strengthening of testing programs and treatment support, along with prevention interventions, are needed to achieve HIV epidemic control